At 12 per month, Kind Patches may seem more affordable than prescription medications, but the lack of clinical evidence makes this poor value compared to proven interventions
NICE Technology Appraisal guidance (TA875 for semaglutide/Wegovy and TA664 for liraglutide/Saxenda) recommends these medications for weight management in adults with: A body mass index (BMI) of at least 35 kg/m and At least one weight-related comorbidity (such as type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea, or non-alcoholic fatty liver disease) For liraglutide (Saxenda), NICE TA664 specifies additional criteria including prediabetes (HbA1c 42-47 mmol/mol or fasting plasma glucose 5.5-6.9 mmol/L) or high risk of cardiovascular disease
The 12-month milestone The one-year GLP-1 before and after comparison is typically the most dramatic
The oral supplements are touted for supposedly offering similar metabolic benefits to injectable GLP-1 prescription drugs
The primary limitation of FAERS is its dependence on voluntary adverse event reporting, which restricts its ability to comprehensively document all occurrences
A narrowly focused portfolio concentrated in the pharmaceutical industry or healthcare sector, may exhibit higher volatility and be vulnerable to factors affecting them due to regulation, litigation, costs and competition
